This report covers the Thyroid cancer market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- It is estimated that in 2016, there were 312,000 incident cases of thyroid cancer worldwide, and forecasts that number to increase to 342,000 incident cases by 2025.
- Asia is estimated to have the highest disease incidence, while Oceania has the lowest incidence. The approved drugs in the thyroid cancer space focus on a wide variety of targets. These drugs are commonly administered via the oral route, with one product being available in an intramuscular formulation.
- The majority of industry-sponsored drugs in active clinical development for thyroid cancer are in Phase II, with only one drug in Phase III.
- Therapies in mid-to-late-stage development for thyroid cancer focus on targets such as mitogen-activated ERK kinase, microtubules (tubulin), carcinoembryonic antigen, Raf kinase, tumor necrosis factor-alpha, RET, and ErbB3/HER3. Half of the drugs in mid-to-late-stage development are administered via the oral route, with the remainder being intravenous or subcutaneous formulations.
- High-impact upcoming events for drugs in the thyroid cancer space comprise topline Phase III results and Phase II results for Selumetinib and GI-6207, respectively.
- There have been 11 licensing and asset acquisition activity deals involving thyroid cancer drugs during 2013-18. The largest deal was the $1,119m exclusive licensing agreement in February 2016 between Exelixis and Ipsen for the commercialization and further development of Cometriq (cabozantinib).
- Nexavar's sales ranked highest among drugs available for thyroid cancer during 2012-17. The distribution of clinical trials across Phase I-IV indicates that the vast majority of trials for thyroid cancer have been in the early and mid-phases of development, with 92% of trials in Phase I-II, and only 8% in Phase III-IV.
- The US has a substantial lead in the number of thyroid cancer clinical trials globally. France leads the major EU markets, while Japan has the top spot in Asia.
- Clinical trial activity in the thyroid cancer space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for thyroid cancer, with 27 completed trials.
- Novartis leads industry sponsors with the highest number of clinical trials for thyroid cancer, followed by Pfizer and GlaxoSmithKline.
Key Topics Covered
- Key Takeaways
- Disease Background
- Marketed Drugs
- Pipeline Drugs
- Key Upcoming Events
- Licensing and Asset Acquisition Deals
- Parent Patents
- Revenue Opportunity
- Clinical Trial Landscape
For more information about this report visit https://www.researchandmarkets.com/research/8zcsnc/global_thyroid?w=4